Coexpression of MYC and BCL-2 predicts prognosis in primary gastrointestinal diffuse large B-cell lymphoma

Table 5 Univariate analysis of prognostic factors for progression-free survival and overall survival in patients with primary gastrointestinal diffuse large B-cell lymphoma

Prognostic factors	n	OS		PFS
		χ2	P	χ2	P
Age (yr)		0.376	0.540	7.377	0.007
≤ 60	34
> 60	26
Gender		0.059	0.808	0.189	0.664
Male	32
Female	28
Primary site		0.132	0.717	1.211	0.271
Stomach	36
Intestinal	24
Lugano staging system		13.355	< 0.0001	17.581	< 0.0001
I-II2	36
IIE-IV	24
LDH		0.029	0.864	0.118	0.731
Normal	34
Elevated	26
B symptoms		1.667	0.197	0.787	0.375
Positive	7
Negative	53
IPI		27.098	< 0.0001	39.737	< 0.0001
0-2	50
3-5	10
Pathological type		0.033	0.856	0.020	0.888
Non-GCB	48
GCB	12
Anemia		0.526	0.468	0.101	0.751
Present	33
Absent	27
Treatment		0.249	0.618	6.758	0.0093
ST + CT	51
ST + CT + RT	9
MYC protein expression		0.347	0.556	0.078	0.780
MYC+	21
MYC-	39
BCL-2 protein expression		10.701	0.001	19.463	< 0.0001
BCL-2+	27
BCL-2-	33
MYC/BCL-2 coexpression		10.956	0.001	15.198	< 0.0001
MYC+/BCL-2+	18
All others	42

OS: Overall survival; PFS: Progression-free survival; ST: Surgery; CT: Chemotherapy; RT: Radiotherapy; CR: Complete remission; IPI: International prognostic index; PR: Partial remission; SD: Stable disease; PD: Progressive disease.